Akcje

Ventyx Biosciences, Inc. ( VTYX ) NASDAQ Global Select
Cena: 1.4 ( 15.7% )

Aktualizacja 05-16 22:00
NASDAQ Global Select
Branża: Biotechnologia

Finanse

Rachunek zysków i strat

Bilans

Przepływy pieniężne

Prognozy

Statystyki

Dywidendy

Rekomendacje

Wyceny

Wskaźniki

Analiza techniczna

Notowania:

Informacje o spółce:

Sektor:	Zdrowie
Branża:	Biotechnologia
Zatrudnienie:	75
Giełda:	NASDAQ Global Select
Ilość akcji w obrocie:	79%
Ilość akcji:	58 971 931
Debiut giełdowy:	2021-10-21
WWW:	https://www.ventyxbio.com
CEO:	Dr. Raju S. Mohan Ph.D.
Adres:	662 Encinitas Boulevard
Siedziba:	92024 Encinitas
ISIN:	US92332V1070

Opis firmy:

Venturyx Biosciences, Inc., firma biofarmaceutyczna na stadium klinicznym, opracowuje kandydatów na małe cząsteczki do chorób zapalnych i zaburzeń autoimmunologicznych. Głównym kandydatem na produkt firmy jest VTX958, inhibitor kinazy tyrozynowej typu 2, który jest w badaniach klinicznych fazy I w leczeniu chorób związanych z odpornością, takich jak łuszczyca, choroba zapalna jelit, łuszczycowe zapalenie stawów, chorobę Loku Crohna i toczek. Opracowuje również modulator fosforanu VTX002, modulator fosforanowy doustny 1, który znajduje się w badaniach klinicznych fazy II w leczeniu wrzodziejącego zapalenia jelita grubego; oraz VTX2735, ukierunkowane na peryferyjne inhibitor inhibitora inflammasomu typu 3 (NLRP3) do leczenia ogólnoustrojowych chorób zapalnych, takich jak choroby sercowo-naczyniowe, wątrobowe, nerkowe i reumatologiczne, które są w badaniach klinicznych fazy I. Ponadto firma opracowuje inhibitory NLRP3 CNS-penetrant do leczenia choroby Alzheimera, choroby Parkinsona, stwardnienia zanikowego bocznego i stwardnienia rozsianego. Veryx Biosciences, Inc. został zarejestrowany w 2018 r. I ma siedzibę w Encinitas w Kalifornii.

Wskaźniki finansowe

Kapitalizacja (USD)	99 625 680
Aktywa:	301 100 000
Cena:	1.4
Wskaźnik Altman Z-Score:	2.8 Umiarkowany (ryzyko bankructwa średnie)
Dywidenda:	0
P/E:	-0.8
Ilość akcji w obrocie:	79%
Średni wolumen:	1 003 120
Ilość akcji	71 161 200

Wskaźniki finansowe

Przychody TTM	1 076 000
Zobowiązania:	22 328 000
Przedział 52 tyg.:	0.783 - 5.66
Piotroski F-Score:	2 Słaby (niska jakość finansowa)
EPS:	-1.7
P/E branży:	26.1
Beta:	0.366
Raport okresowy:	2025-08-07
WWW:	https://www.ventyxbio.com

Zarząd

Imie i Nazwisko	Stanowisko	Wynagrodzenie	Rok urodzenia
Dr. Raju S. Mohan Ph.D.	Founder, Chief Executive Officer, President & Director	905 293	1958
Dr. John M. Nuss Ph.D.	Chief Scientific Officer	630 635	1959
Dr. Sheila K. Gujrathi M.D.	Executive Chairperson	125 000	1970
Mr. Matthew Richard Moore	Chief Operating Officer	0	1973
Dr. Martin Douglas Auster M.D.	Chief Financial Officer	0	1975

Wiadomości dla Ventyx Biosciences, Inc.

Pokaż rekordów

Tytuł	Treść	Źródło	Aktualizacja	Link
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress	Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson's disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported first quarter financial results and highlighted recent pipeline and business progress. “Ventyx has established itself as the leader in discovery and development of NLRP3 inhibitors with two novel compounds, VTX3232 and VTX2735 progressing through Phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications - disease states thought to be driven by pathologic activation of the NLRP3 inflammasome,” said Raju Mohan, PhD, President and Chief Executive Officer.	globenewswire.com	2025-05-08 20:01:00	Czytaj oryginał (ang.)
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists	Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program -- AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB): Mo Lamkanfi, PhD, Luke O'Neill, PhD, Ted Dawson, MD, PhD, Martin Pomper, MD, PhD, Antonio Abbate, MD, PhD, Paul Cremer, MD and Don Frail, PhD. The new SAB members have made vital discoveries in understanding the role of the NLRP3 inflammasome in neuro- and systemic inflammation, and are at the forefront of clinical development in neurodegenerative and cardiometabolic diseases.	globenewswire.com	2025-04-01 11:00:00	Czytaj oryginał (ang.)
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress	Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 biomarker study in patients with early Parkinson's disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported fourth quarter and full year 2024 financial results and highlighted recent pipeline and business progress. “Heading into 2025, Ventyx has established itself as the leader in the field of NLRP3 inhibition having progressed two novel inhibitors, VTX3232 and VTX2735, into Phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications.	globenewswire.com	2025-02-27 18:05:00	Czytaj oryginał (ang.)
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025	Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn's disease will be presented during the 20th Congress of the European Crohn's and Colitis Organisation (ECCO) being held in Berlin, Germany from February 19-22, 2025. “The Phase 2 data for VTX958 in Crohn's disease represent an important milestone for TYK2 inhibition in inflammatory bowel disease,” said Raju Mohan, PhD, Founder and Chief Executive Officer.	globenewswire.com	2025-02-18 10:00:00	Czytaj oryginał (ang.)
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference	SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.	globenewswire.com	2025-02-05 10:00:00	Czytaj oryginał (ang.)

Wyświetlono od 1 do 5 z 26 rekordów

Poprzedni1 2 3 4 5 6Następny